![https://static.aminer.cn/upload/avatar/937/280/1402/5619806545ce1e59643a8ef1_0.jpg](https://avatarcdn.aminer.cn/upload/avatar/937/280/1402/5619806545ce1e59643a8ef1_0.jpg!160)
Daniel Wanyui Chan
Professor
Clinical Chemistry Division
Department of Pathology, The Johns Hopkins University School of Medicine;Pathology Core Laboratory, Department of Pathology, The Johns Hopkins University School of Medicine;Center for Biomarker Discovery & Translation, The Johns Hopkins University School of Medicine
Follow
Claim
分享
Follow
Claim
分享
基本信息
views: 371
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Chan is a diplomat of the American Board of Clinical Chemistry (ABCC) and a fellow of the National Academy of Clinical Biochemistry (NACB). He is an internationally recognized expert in cancer biomarkers, clinical proteomics and molecular diagnostics. He has written 5 books, 40 book chapters and over 300 scientific articles. He is funded by the National Cancer Institute (NCI) as the Principal investigator of the CPTAC (Cancer Proteomic Tumor Analysis Consortium), the Biomarker Characterization Center (BCC) for the EDRN (Early Detection Research Network) and the Pancreatic Cancer Detection Consortium (PCDC).
The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, and ovarian cancer biomarkers. In 1977, he conducted the clinical study of CA27.29 as a marker for breast cancer recurrence leading to the first FDA approval of a serum breast cancer assay. In 2000, he founded the Center for Biomarker Discovery and Translation. The focus of this Center is the discovery of proteomics biomarkers using mass spectrometry and protein microarrays, followed by the validation and translation of these novel biomarkers for the detection, diagnosis, classification, management and understanding of human diseases. In 2009, he developed the OVA1 test for ovarian cancer – the first FDA cleared proteomic in vitro diagnostic multivariate index assay (IVDMIA). In 2012, he developed public-private partnerships (NCI EDRN, industry and academic centers) leading to the clinical study, publication and FDA approval of new prostate cancer tests – proPSA (phi) with Beckman Coulter Inc. and PCA3 (PROGENSA) with Gen-probe (Hologic, Inc).
The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, and ovarian cancer biomarkers. In 1977, he conducted the clinical study of CA27.29 as a marker for breast cancer recurrence leading to the first FDA approval of a serum breast cancer assay. In 2000, he founded the Center for Biomarker Discovery and Translation. The focus of this Center is the discovery of proteomics biomarkers using mass spectrometry and protein microarrays, followed by the validation and translation of these novel biomarkers for the detection, diagnosis, classification, management and understanding of human diseases. In 2009, he developed the OVA1 test for ovarian cancer – the first FDA cleared proteomic in vitro diagnostic multivariate index assay (IVDMIA). In 2012, he developed public-private partnerships (NCI EDRN, industry and academic centers) leading to the clinical study, publication and FDA approval of new prostate cancer tests – proPSA (phi) with Beckman Coulter Inc. and PCA3 (PROGENSA) with Gen-probe (Hologic, Inc).
Research Interests
Papers共 879 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Shaozhen Jing, Xiaolei Wu,Shiu-Hin Daniel Chan,Sang-Cuo Nao, Jianxiong Du,Chun-Yuen Wong,Jing Wang,Chung-Hang Leung,Wanhe Wang
Inorganic Chemistry Frontiers (2024)
PROSTATE CANCER AND PROSTATIC DISEASESno. 1 (2024): 65-72
Jeffrey J Tosoian,Yuping Zhang,Lanbo Xiao,Cassie Xie,Nathan L Samora,Yashar S Niknafs,Zoey Chopra,Javed Siddiqui,Heng Zheng, Grace Herron,Neil Vaishampayan, Hunter S Robinson,
JAMA oncologyno. 6 (2024): 726-736
Cancer Researchno. 12 (2023): 5600-5605
crossref(2023)
crossref(2023)
CANCER RESEARCHno. 7 (2023): 101547-101547
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn